Background: Accumulating evidence indicates that trimethylamine-N-oxide (TMAO) may play a causal role in cardiovascular disease (CVD), chronic kidney disease (CKD) and type 2 diabetes (T2D). TMAO plasma concentrations show considerable intra-and inter-individual variation, underscoring the need for a reference interval in the general population to identify elevated TMAO concentrations. Methods: TMAO concentrations were determined using an LC-MS/MS assay in a community-based sample of the PopGen control cohort consisting of 694 participants (54% men; aged 25-82 years) free of clinical CVD, CKD and T2D. We defined reference intervals for TMAO concentrations in human plasma using the 2.5th and 97.5th percentiles. Using multivariable regression analysis we analyzed the association of estimated glomerular filtration rate (eGFR), sex, and dietary intake and TMAO plasma concentrations. Results: TMAO plasma concentrations were positively skewed and differed by sex. The median TMAO plasma concentration in men was 3.91 (Q1-Q3: 2.87-6.10) μmol/L and the reference interval 1.28-19.67 μmol/L (2.5th-97.5th percentile). In women median TMAO plasma concentration was 3.56 (Q1-Q3: 2.41-5.15) μmol/L and the reference interval 1.08-17.12 μmol/L. In multivariable regression analysis plasma TMAO was associated with sex, renal function and diet. The association of TMAO and diet was significant for intake of fish and shellfish in men only. Conclusions: In a community-based sample free of apparent CVD and renal disease, we report the distribution of TMAO plasma concentrations with sex, renal function and diet as factors associated with plasma TMAO, and suggest reference intervals. These data may facilitate standardized comparisons of TMAO across populations.
Introduction
Elevated plasma concentrations of trimethylamine-N-oxide (TMAO) confer an increased risk for cardiovascular disease (CVD), chronic kidney disease (CKD) and type 2 diabetes (T2D) [1] [2] [3] [4] [5] . Mounting evidence indicates that TMAO may play a causal role in these chronic disease conditions. It has been shown in experimental settings, that high plasma concentrations of TMAO may promote formation of atherosclerotic plaques [1, 6] , platelet activation [7, 8] and renal fibrosis [4] . However, it should be mentioned that TMAO is also discussed as being beneficial for the cardiovascular system and that it is actually trimethylamine (TMA), the metabolic precursor of TMAO, exerting the above described detrimental effects (please see [9] for a review on this topic).
TMAO is a dietary component [10, 11] and is also generated in a gut-microbiome-dependent pathway in which TMA is formed from nutritional substrates (e.g. choline or carnitine) and subsequently oxidized by hepatic flavin monooxygenase 3 (FMO3) to TMAO [6, 12] . A diet rich in animal products, which contains relatively large amounts of precursors of TMA, is associated with higher plasma levels of TMAO [13] [14] [15] . However, the formation of TMAO from dietary products depends on the presence of gut microbes capable of metabolizing TMA precursors [10, 15, 16] . Furthermore, it is currently unclear if male or female sex may have an influence on TMAO plasma concentrations, as there are studies finding significant associations in a healthy population [15, 17, 18] , while others do not [13, 19] .
Besides the composition of gut microbiome, dietary intake and sex, kidney function is an important determinant of the plasma TMAO concentrations as it is almost exclusively removed from the circulation via renal elimination [11, 15, 20] , putatively involving active secretion mechanisms [21] [22] [23] [24] .
TMAO plasma concentrations in humans show a considerable intra-and inter-individual variation, both in healthy and in diseased individuals [19, 25, 26] . Therefore, to describe the distribution of TMAO plasma concentrations in a general population, a sample free of apparent CVD or renal disease may be useful to define increased TMAO concentrations. Important work in this respect has already been done by Wang et al. [19] , who reported the distribution of plasma TMAO in 349 apparently healthy individuals. However, in the latter study, data on some important covariates that are necessary for an establishment of reference limits according to the standards of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), were not available.
We used a well-defined sample of the population-based German PopGen control cohort [27, 28] to report the distribution and identify reference limits of TMAO plasma concentrations in a community-based sample free of apparent coronary heart disease (CHD), heart failure, heart attack, stroke, diabetes and renal insufficiency. TMAO was determined using a validated LC-MS/MS assay with high accuracy and precision. Furthermore, we identified important correlates of TMAO plasma concentrations in our sample.
Materials and methods

Study sample
The design and recruitment of the PopGen control cohort has been described in detail elsewhere [27, 28] . The original sample size at the baseline examination was 1316 individuals. Of these, 569 individuals were blood donors from the local university hospital; and 747 participants were from a random sample obtained through population registries [27, 28] . A total of 952 participants attended the first followup examination (second examination cycle) conducted between 2010 and 2012. We excluded 32 individuals from the analytical study population, due to missing TMAO value (n = 26) or missing covariate data (n = 6). In a stepwise procedure we excluded 226 individuals with a self-reported history of diseases (CVD, diabetes mellitus, CKD) known to be strongly associated with an alteration of the TMAO plasma concentration ( Figure 1 ) [1] [2] [3] [4] [5] . Thus, the final analytical sample included 694 participants.
Interview, physical examination and collection of plasma samples
At the second examination cycle, all participants underwent a standardized physical examination by specifically trained personnel and completed a health-related questionnaire. This questionnaire included, among others, questions related to physician-diagnosed heart failure, CHD, stroke and diabetes. Dietary intake over the past year was assessed by using a validated 112-item food frequency questionnaire established for German populations [29] . Intake of dairy products, meat and meat-products, fish and shellfish, and eggs and egg-products were derived from the self-administered food frequency questionnaire [27, 29] . In addition, plasma samples were collected from all participants.
All participants underwent standardized measurements of clinical parameters, as previously described in detail [27, 28] . Heart failure, heart attack, CHD and stroke were defined as selfreported diagnosis or diagnosed by a physician. A major adverse cardiovascular event (MACE) was defined as a history of heart attack or stroke as self-reported diagnosis or diagnosed by a physician. Diabetes was defined as HbA 1c ≥ 6.5%, fasting blood glucose concentration ≥126 mg/dL, self-reported diagnosis, or diagnosed by a physician. Fasting status was self-reported and defined as not eating or drinking anything for at least 8 h before the blood draw. Individuals with missing TMAO data, missing covariate data, or major chronic diseases were excluded from the study population by a stepwise exclusion procedure.
The CKD-EPI equation was used to calculate estimated glomerular filtration rate (eGFR) [30] . The study protocol was approved by the Ethics Committee of the Medical Faculty of Kiel University and is in accordance with the Helsinki Declaration. All participants provided written informed consent.
Measurement of plasma TMAO concentration
We performed mass spectrometric measurement of TMAO in plasma samples using a validated LC-MS/MS assay. In brief, in 20 μL of plasma proteins were precipitated with methanol containing [ 2 H 9 ]TMAO as an internal standard. After centrifugation an aliquot of the supernatant was diluted with acetonitrile and subsequently analyzed (see Supplementary Material for details on the method).
Statistical analyses
We used SPSS Statistics Version 25 (IBM) for statistical analyses. A p-value of <0.05 indicated statistical significance. We used a twosided t-test for independent samples on normally distributed samples. For non-normally distributed samples we used a Mann-Whitney test. Data are presented as mean (standard deviation [SD]) or mean (standard error [SE]) unless otherwise indicated.
We calculated reference limits according to recommendations by Solberg [31] . TMAO concentrations were not normally distributed in our sample as assessed on histograms and normal probability plots. To account for their non-normal distribution, TMAO values were logarithmically transformed (logTMAO).
In order to assess statistically significant clinical and nutritional correlates of circulating TMAO concentrations, we used multivariable linear regression models with logTMAO as the outcome variable with stepwise forward selection (significance criterion for entry into the model, p = <0.1) and the following variables as potential correlates: age, sex, body mass index (BMI), glucose, HbA 1c , low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides, systolic blood pressure (SBP), diastolic blood pressure (DBP), eGFR, as well as consumption of dairy products, meat and meat-products, fish and shellfish, and eggs and egg-products. These food groups were previously reported as potential correlates of TMAO plasma concentrations [13] [14] [15] . Total cholesterol was excluded from the model due to collinearity with LDL-cholesterol and HDL-cholesterol.
Results
Validation and performance of the LC-MS/MS method
The validated concentration range for determination of TMAO was 0.1-25.0 μmol/L. During validation the maximum coefficient of variation (CV) found for inter-and intraday precision was 4.5%. Accuracy ranged between 98.6 and 114.4%. For quality control (QC) samples during analysis of plasma samples the maximum CV was 17.7% at the lower limit of quantification and 5.1% at all other concentration levels. The accuracy for all QC samples ranged between 88.6 and 108.3%. Please see the Supplementary Material for more details on the performance of the LC-MS/MS method.
Clinical characteristics
The clinical characteristics of the study sample are displayed in Table 1 , stratified by sex. The population is mainly composed of white, middle-aged individuals of European descent. The mean age was 58 years and 54% of the participants were men. Men had higher mean values for BMI, SBP, DBP, glucose and triglycerides, while women had higher values for total and HDL-cholesterol.
Distribution of TMAO
Untransformed TMAO values were right-skewed in men and women ( Figure 2 ). Both the mean and the median TMAO value were significantly higher in men compared with women (both p < 0.01). Median TMAO plasma concentrations were 3.91 (Q1-Q3: 2.87-6.10) μmol/L in men (reference interval 1.28-19.67 [2.5th-97.5th percentile]) and 3.56 (Q1-Q3: 2.41-5.15) μmol/L in women (reference interval 1.08-17.12). The histogram of the distribution of TMAO plasma concentrations for men and women is depicted in Figure 2 . Table 2 shows details on the distribution of TMAO plasma concentrations in the total population and both sexes.
The consumption of food of animal origin is shown in Table 3 . Men had a significantly higher mean consumption of meat and meat-products, fish and shellfish (p < 0.001), and dairy products (p < 0.05) compared with women. Intake of eggs and egg-products did not differ by sex.
Subjects in a fasted state (n = 460) had numerically, but not statistically significant (p = 0.098), higher TMAO plasma concentrations (median 3.80 μmol/L) than subjects in a non-fasted state (median 3.56 μmol/L).
Clinical and nutritional correlates of TMAO
The results of a multivariable regression model are shown in Table 4 . Based on a cut-off for model entry of p < 0.1, eGFR, sex, and the consumption of fish and shellfish were included in the final model. eGFR and female sex were inversely associated with logTMAO. Consumption of fish and shellfish was positively related to logTMAO.
The strongest correlations with logTMAO were observed for eGFR (unadjusted Spearman r = -0.256, p < 0.001 for men and r = −0.273, p < 0.001 for women) and age (unadjusted Spearman r = 0.205, p < 0.001 for men and r = 0.237, p < 0.001 for women). The correlation between logTMAO and eGFR remained significant after adjustment for age in both, men and women (r = −0.129, p < 0.05 and r = −0.172, p < 0.01, respectively). The correlation between logTMAO and age is no longer significant after adjustment for eGFR (r = 0.059, p = 0.256 in men and r = 0.073, p = 0.196 in women). After adjustment for eGFR, logTMAO correlated significantly with the consumption of fish and shellfish (r = 0.122, p < 0.05) in men. In women, no statistically significant correlation was observed between logTMAO and consumption of fish and shellfish after adjustment for eGFR (r = 0.027, p = 0.630). All other food of animal origin that was investigated had no significant correlations in neither of the two sexes (data not shown). The correlation between Data are mean (SD), for TMAO median (IQR) is shown. eGFR was calculated using the CKD-EPI formula [30] . BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA 1c , glycated hemoglobin; eGFR, estimated glomerular filtration rate; HDL, highdensity lipoprotein; LDL, low-density lipoprotein; TMAO, trimethylamine-N-oxide.
logTMAO and sex was statistically significant (unadjusted Spearman r = −0.107 for female sex, p < 0.01) and remained significant after adjustment for eGFR (r = −0.111, p < 0.01).
Discussion
Various experimental and clinical data associate TMAO with an increased risk for CVD, CKD and T2D [1] [2] [3] [4] [5] . However, little is known about the distribution and clinical and nutritional correlates of circulating TMAO levels in a relatively unselected sample from the general population.
Distribution of TMAO levels in health and disease
In prior studies, median TMAO plasma concentrations of 5.0 μmol/L and 7.9 μmol/L were associated with a higher risk of MACE and CKD, respectively [2, 4] . In 349 apparently healthy individuals, a median TMAO concentration of 3.45 μmol/L was reported [19] .
In our community-based sample, free of apparent heart failure, heart attack/CHD, stroke, diabetes and renal insufficiency, we report 95% TMAO reference intervals for men as 1. .67 μmol/L and for women as 1.08-17.12 μmol/L (both 2.5th and 97.5th percentiles). These values are similar to another group of healthy individuals that was investigated by Wang et al. [19] , but it also overlaps with values reported in patients with a confirmed cardiovascular event (interquartile range [IQR] 3.0-8.8 μmol/L) [2] , in patients with an eGFR below 60 mL/min (IQR 5.2-12.4 μmol/L) [4] , or in patients with CKD stage IV/V (IQR 12.5-47.3 μmol/L) [32] . Despite this overlap, the TMAO distribution in our sample is comparable to control groups of apparently healthy individuals reported by other studies [2, 4, 19] . Ultimately, prospective studies are required to evaluate whether baseline levels within the TMAO range presented in our apparently healthy sample confer an increased risk for new-onset CVD, CKD or T2D over the life course. So far, there is not yet a sufficient number of individuals with CVD, CKD or T2D in the PopGen cohort to draw statistically sound conclusions on this matter.
Factors that correlate with circulating TMAO plasma concentrations
TMAO plasma concentrations may be determined by several factors -uptake (i.e. diet), endogenous generation and degradation (i.e. gut microbiome and endogenous enzymatic capacity), as well as renal elimination. Moreover, it may well be that the different factors contributing to plasma TMAO (such as diet and microbiome) represent factors associated with independent and possibly divergent effects on outcome. In this case plasma TMAO may simply represent the net effect of these beneficial and adverse factors combined. In our statistical models we identified kidney function as the most important correlate of TMAO plasma concentrations. This is expected, as TMAO is almost exclusively eliminated by the kidneys in an unmodified form via filtration and active secretion mechanisms [11, 15, 16, [20] [21] [22] [23] [24] . Our analysis shows that among individuals with an eGFR of >60 mL/min per each increase of 1 mL/min in eGFR logTMAO values are 0.005 (0.3%) units lower. TMAO plasma concentrations in CKD patients were found to be elevated to comparatively high levels [4, 32] , which further underlines the importance of kidney function for circulating TMAO levels.
In addition to renal function, we observed statistically significant differences in TMAO levels between men and women and found an association of TMAO plasma concentration with the consumption of fish and shellfish in men, but not in women. TMAO is known to be abundant in marine animals where it serves as a protective agent against osmotic stress [10, 33] . As it can be readily absorbed from food, a diet rich in TMAO clearly can influence TMAO plasma concentrations [10] . Direct absorption of TMAO from fish and shellfish is expected to happen within 1 h and is excreted to urine within 24 h [10, 11] . After 6 h only about 5.5% of the directly absorbed TMAO dose is found in plasma [11] . Unexpectedly, the direct association of fish and shellfish intake with TMAO plasma concentrations was limited to men only. Other studies with smaller sample sizes report either no effect of fish and shellfish consumption on TMAO plasma concentration [13] or a high variation of TMAO plasma concentrations [10] . Future studies using alternative methods to assess the individual diets may help to assess the effect of recall bias on the observations regarding the association of food intake and TMAO plasma concentrations. Furthermore, the clinical relevance of the observed association of fish and shellfish intake with TMAO plasma concentrations in men remains to be investigated in future studies, when more data regarding onset or outcome of CVD, CKD or T2D in the PopGen cohort will be available. The observed lack of statistical significance of the association between fish and shellfish intake and TMAO plasma concentrations in women might be explained by the higher intake of fish and shellfish in men compared with women. In general men had a higher consumption of food containing TMAO or TMAO precursors (Table 3) . Furthermore, the differential association of TMAO with fish and shellfish consumption in men and women needs to be discussed in conjunction with the significant sex differences of TMAO plasma concentrations that we observed in our community-based sample. Differences in TMAO plasma concentrations between men and women have been observed in some studies [15, 17, 18] , but not in others [13, 19] .
In humans the FMO3 protein abundance (the enzyme oxidizing TMA to TMAO) was reported to be only moderately, yet significantly, higher in women [34] . Based on these previous findings, higher TMAO plasma concentrations in men should not be expected. Another important factor that may affect the TMAO plasma concentrations is the composition of the gut microbiome [10, 15, 35 ]. Short-term intake of TMA-precursors may lead to severalfold elevation of TMAO plasma concentrations between 6 and 24 h after their intake if metabolizing bacteria are present in the gut [10, 14, 36] . This implies that food intake within the last 24 h before sampling is very important for interpretation of TMAO plasma concentrations. Thus, the lack of a statistically significant association between fish and shellfish intake and TMAO plasma concentrations in women might be explained by the fact that the food frequency questionnaire used reflects long-term rather than recent dietary intake. However, long-term nutritional habits can influence the gut microbiome [36, 37] , which itself influences the amount of TMA being produced from available precursors present in short-term diet. As sex is another determining factor of the composition of the gut microbiome [38, 39] , this may influence the constantly produced amount of TMA (and thereby TMAO) from longterm available sources, such as choline in bile, in a kind of enterohepatic cycle. This depends on the presence of bacteria harboring the necessary enzymes and may not be attributable to certain genera being detected in the gut microbiome [36] . However, our study lacks data regarding activity of FMO3, the presence of certain bacterial enzymes, or plasma concentrations of TMA.
For determining long-and short-term variation of TMAO plasma concentrations a carefully designed study accounting for long-and short-term nutritional habits, interactions with FMO3 activity (medication, SNPs) and renal elimination (e.g. via inhibition of transport proteins), a detailed characterization of the gut microbiome, and plasma concentrations of TMA within a well-defined study population would be desirable.
Strengths and limitations
The community-based and clinically and physiologically well-characterized sample and the quantification of TMAO plasma concentrations by a validated LC-MS/MS method are the strengths of our investigation. However, we acknowledge some limitations. We evaluated TMAO plasma concentrations at one time point in each individual which does not allow us to determine intra-individual variations over time. Data regarding FMO3 activity, high resolution data of bacterial genes capable of producing TMA present in the gut microbiome, and TMA plasma concentrations are not available. All medical diagnoses were self-reported by the study participants as diagnosed by their physicians, but not validated against original medical records. Dietary intake was assessed using selfadministered questionnaires, which are prone to recall bias. Recall bias could lead to over-or underestimation of associations between food intake and TMAO plasma concentration. Validation of the food frequency questionnaire used in the present study indicated that the food frequency questionnaire provides a useful estimate of dietary intake [29] . Future studies need to assess if food intake is related to TMAO plasma concentrations in prospective settings. Our sample is mainly composed of white, middle-aged individuals of European descent, warranting caution on extrapolating the results to other ethnicities or a different range of age. However, study participants were in the range of age comparable to other studies establishing reference intervals for risk markers and the risk of metabolic disorders may increase with TMAO plasma concentrations even if it is within the herein defined reference interval. The approach used to define reference intervals was distribution based.
Conclusions
In a community-based sample of individuals free of apparent CVD and renal disease or diabetes, we report the distribution of TMAO plasma concentrations and suggest reference values. These data may facilitate standardized comparisons of TMAO across populations and should be evaluated in relation to incident (new-onset) cardiometabolic risk. Consequently, the provided reference ranges for TMAO in a community-based sample may contribute to the discussion, if TMAO should be considered as a harmful, diagnostic or protective marker. The relatively wide distribution of TMAO plasma concentrations suggests several factors altering TMAO homeostasis, which should be considered and accounted for when evaluating individual TMAO values. These factors include sex, diet and renal elimination. Several other factors not yet identified might also alter TMAO plasma concentrations.
